Taiwan
· Delayed Price · Currency is TWD PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 169.30 billion. The enterprise value is 149.46 billion.
| Market Cap | 169.30B |
| Enterprise Value | 149.46B |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Aug 11, 2025 |
Share Statistics
PharmaEssentia has 333.27 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Current Share Class | 333.27M |
| Shares Outstanding | 333.27M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 8.74% |
| Owned by Institutions (%) | 7.98% |
| Float | 262.27M |
Valuation Ratios
The trailing PE ratio is 41.92 and the forward PE ratio is 21.69.
| PE Ratio | 41.92 |
| Forward PE | 21.69 |
| PS Ratio | 13.40 |
| PB Ratio | 5.93 |
| P/TBV Ratio | 5.99 |
| P/FCF Ratio | 86.65 |
| P/OCF Ratio | 54.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.12, with an EV/FCF ratio of 76.50.
| EV / Earnings | 36.89 |
| EV / Sales | 11.83 |
| EV / EBITDA | 39.12 |
| EV / EBIT | 42.99 |
| EV / FCF | 76.50 |
Financial Position
The company has a current ratio of 7.71, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.71 |
| Quick Ratio | 7.24 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | 0.48 |
| Interest Coverage | 138.58 |
Financial Efficiency
Return on equity (ROE) is 15.04% and return on invested capital (ROIC) is 7.78%.
| Return on Equity (ROE) | 15.04% |
| Return on Assets (ROA) | 7.12% |
| Return on Invested Capital (ROIC) | 7.78% |
| Return on Capital Employed (ROCE) | 11.80% |
| Revenue Per Employee | 96.45M |
| Profits Per Employee | 30.92M |
| Employee Count | 131 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.23 |
Taxes
| Income Tax | -761.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.66% in the last 52 weeks. The beta is -0.06, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -29.66% |
| 50-Day Moving Average | 527.85 |
| 200-Day Moving Average | 575.33 |
| Relative Strength Index (RSI) | 39.78 |
| Average Volume (20 Days) | 1,454,417 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 12.63 billion and earned 4.05 billion in profits. Earnings per share was 12.12.
| Revenue | 12.63B |
| Gross Profit | 11.14B |
| Operating Income | 3.48B |
| Pretax Income | 3.29B |
| Net Income | 4.05B |
| EBITDA | 3.59B |
| EBIT | 3.48B |
| Earnings Per Share (EPS) | 12.12 |
Balance Sheet
The company has 20.78 billion in cash and 944.47 million in debt, giving a net cash position of 19.84 billion or 59.53 per share.
| Cash & Cash Equivalents | 20.78B |
| Total Debt | 944.47M |
| Net Cash | 19.84B |
| Net Cash Per Share | 59.53 |
| Equity (Book Value) | 28.55B |
| Book Value Per Share | 85.65 |
| Working Capital | 22.43B |
Cash Flow
In the last 12 months, operating cash flow was 3.12 billion and capital expenditures -1.17 billion, giving a free cash flow of 1.95 billion.
| Operating Cash Flow | 3.12B |
| Capital Expenditures | -1.17B |
| Free Cash Flow | 1.95B |
| FCF Per Share | 5.86 |
Margins
Gross margin is 88.16%, with operating and profit margins of 27.52% and 32.06%.
| Gross Margin | 88.16% |
| Operating Margin | 27.52% |
| Pretax Margin | 26.04% |
| Profit Margin | 32.06% |
| EBITDA Margin | 28.45% |
| EBIT Margin | 27.52% |
| FCF Margin | 15.46% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 0.22%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 0.22% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -0.94% |
| Earnings Yield | 2.39% |
| FCF Yield | 1.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaEssentia has an Altman Z-Score of 30.12 and a Piotroski F-Score of 6.
| Altman Z-Score | 30.12 |
| Piotroski F-Score | 6 |